Pill Diary

BEHAVIORAL3 trials

Conditions

Advanced Colorectal AdenocarcinomaAdvanced Colorectal CarcinomaBreast CancerColorectal AdenocarcinomaColorectal CancerColorectal Cancer MetastaticGynecologic CancerMalignant Neoplasms of Female Genital Organs

Phase 1

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

RecruitingNCT05200442

University of ChicagoAdvanced Colorectal Adenocarcinoma, Advanced Colorectal Carcinoma, Colorectal Adenocarcinoma +2

Start: 2022-08-22End: 2027-02-01Target: 53Updated: 2026-03-30

Phase 2

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

TerminatedNCT01900730

M.D. Anderson Cancer CenterBreast Cancer

Start: 2014-07-31End: 2018-06-01Updated: 2020-02-25

Phase 3

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

TerminatedNCT02740114

M.D. Anderson Cancer CenterGynecologic Cancer, Malignant Neoplasms of Female Genital Organs

Start: 2016-08-31End: 2020-07-23Updated: 2021-10-18

Related Papers

Avutometinib plus cetuximab after chemotherapy in patients with <i>KRAS</i> -mutated metastatic colorectal cancer: Results of phase 1 dose escalation.

Journal of Clinical Oncology2025-01-27

Abstract 530: Preclinical evaluation of avutometinib (VS-6766; RAF/MEK clamp) in combination with EGFR inhibition in colorectal cancer patient-derived xenograft (PDX) models harboring <i>KRAS</i> mutations